Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017.J Natl Compr Canc Netw. 2017; 15: 9-20
- Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.Cancer. 2016; 122: 3673-3681
- Breast cancer genetics for the surgeon: an update on causes and testing options.J Am Coll Surg. 2016; 222: 906-914
- Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.Curr Oncol Rep. 2014; 16: 371
- Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.Lancet Oncol. 2007; 8: 1042-1043
- No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.Breast Cancer Res Treat. 2011; 125: 169-173
- Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Br J Cancer. 2009; 100: 421-425
- Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.Am J Surg. 2016; 212: 660-669
- Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.N Engl J Med. 1999; 340: 77-84
- Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.J Natl Cancer Inst. 2001; 93: 1633-1637
- Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.N Engl J Med. 2001; 345: 159-164
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA. 2010; 304: 967-975
- Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.Ann Surg Oncol. 2015; 22: 370-376
- Total skin-sparing mastectomy in BRCA mutation carriers.Ann Surg Oncol. 2014; 21: 37-41
- Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.Br J Surg. 2015; 102: 1354-1359
- Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.JAMA. 2014; 312: 902-914
- Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.Ann Surg Oncol. 2009; 16: 2697-2704
- Contralateral prophylactic mastectomy: current perspectives.Int J Womens Health. 2016; 8: 213-223
- Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer.JAMA Surg. 2017; 152: 274-282
- Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.J Clin Oncol. 2011; 29: 1564-1569
- Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.J Clin Oncol. 2013; 31: 433-439
- Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.J Clin Oncol. 2009; 27: 5887-5892
- Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.Lancet Oncol. 2015; 16: 638-644
- Clinicopathologic features and time interval analysis of contralateral breast cancers.Surgery. 2015; 158: 676-685
- Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.BMJ. 2014; 348: g226
- Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.Breast Cancer Res Treat. 2013; 140: 135-142
- Patient satisfaction in unilateral and bilateral breast reconstruction [outcomes article].Plast Reconstr Surg. 2011; 127: 1417-1424
- Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction.Ann Surg Oncol. 2013; 20: 3422-3429
- Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy.Ann Surg Oncol. 2014; 21: 3297-3303
- Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database.Ann Surg Oncol. 2013; 20: 3212-3217
- The effect of contralateral prophylactic mastectomy on perioperative complications in women undergoing immediate breast reconstruction: a NSQIP analysis.Ann Surg Oncol. 2015; 22: 3474-3480
- Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer.Fam Cancer. 2013; 12: 479-487
- Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.J Clin Oncol. 2008; 26: 3943-3949
- Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy.JAMA. 2000; 284: 319-324
- Impact of reconstruction and reoperation on long-term patient-reported satisfaction after contralateral prophylactic mastectomy.Ann Surg Oncol. 2015; 22: 401-408
- Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.Cancer. 2012; 118: 2021-2030
- Screening breast ultrasound: past, present, and future.AJR Am J Roentgenol. 2015; 204: 234-240
- Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT).Eur J Cancer. 2000; 36: S49-S50
- The NSABP study of tamoxifen and raloxifene (STAR) trial.Expert Rev Anticancer Ther. 2009; 9: 51-60
- Exemestane for breast-cancer prevention in postmenopausal women.N Engl J Med. 2011; 364: 2381-2391
Article info
Publication history
Published online: May 30, 2018
Footnotes
Disclosure Statement: The authors have nothing to disclose.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
